Strs Ohio Has $2.09 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Strs Ohio increased its stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR) by 205.8%, adding 21,200 shares to hold 31,500 shares worth about $2.09 million.
• Arrowhead's latest quarter missed EPS ($0.22 vs. $0.60) but revenue beat estimates at $264.03M (vs. $225.66M) with a year‑over‑year revenue surge of 10,461%; the stock trades near its 52‑week high (~$74.93) with a market cap of ~$10.5B.
• Institutional buying has been heavy (e.g., Arrowstreet, Pictet, Baker Bros materially increased positions) and Wall Street is bullish overall—consensus rating "Moderate Buy" with price targets raised up to $110 (average target ~$84.20).

Strs Ohio grew its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 205.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 31,500 shares of the biotechnology company's stock after purchasing an additional 21,200 shares during the period. Strs Ohio's holdings in Arrowhead Pharmaceuticals were worth $2,091,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Arrowstreet Capital Limited Partnership boosted its stake in Arrowhead Pharmaceuticals by 3,142.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company's stock valued at $71,797,000 after buying an additional 2,017,489 shares in the last quarter. Deerfield Management Company L.P. acquired a new position in Arrowhead Pharmaceuticals during the third quarter worth $34,249,000. Balyasny Asset Management L.P. bought a new position in shares of Arrowhead Pharmaceuticals during the third quarter valued at $27,349,000. Pictet Asset Management Holding SA lifted its holdings in shares of Arrowhead Pharmaceuticals by 253.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,028,736 shares of the biotechnology company's stock valued at $68,636,000 after acquiring an additional 737,713 shares during the period. Finally, Baker BROS. Advisors LP boosted its stake in shares of Arrowhead Pharmaceuticals by 77.9% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,670,762 shares of the biotechnology company's stock valued at $57,625,000 after purchasing an additional 731,588 shares in the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR opened at $74.93 on Wednesday. The stock has a 50 day simple moving average of $63.70 and a 200 day simple moving average of $59.78. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $12.44 and a 52-week high of $77.90. The firm has a market capitalization of $10.49 billion, a PE ratio of 48.97 and a beta of 1.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing analysts' consensus estimates of $0.60 by ($0.38). The company had revenue of $264.03 million during the quarter, compared to analyst estimates of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.Arrowhead Pharmaceuticals's revenue for the quarter was up 10461.3% on a year-over-year basis. During the same period in the previous year, the company posted ($1.39) earnings per share. Sell-side analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.37 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider James C. Hamilton sold 10,000 shares of the firm's stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total value of $750,000.00. Following the completion of the transaction, the insider owned 226,958 shares of the company's stock, valued at approximately $17,021,850. This trade represents a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of Arrowhead Pharmaceuticals stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total transaction of $934,328.25. Following the completion of the sale, the chief financial officer owned 162,905 shares in the company, valued at $11,623,271.75. The trade was a 7.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 33,095 shares of company stock valued at $2,326,228. Insiders own 3.60% of the company's stock.

Wall Street Analyst Weigh In

ARWR has been the subject of several recent analyst reports. JPMorgan Chase & Co. assumed coverage on shares of Arrowhead Pharmaceuticals in a report on Friday, May 1st. They set an "overweight" rating and a $88.00 price objective for the company. Morgan Stanley upgraded Arrowhead Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $78.00 to $100.00 in a research report on Tuesday, April 21st. HC Wainwright reaffirmed a "buy" rating and set a $100.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, March 25th. B. Riley Financial boosted their price objective on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a "buy" rating in a research note on Thursday, January 22nd. Finally, Piper Sandler restated an "overweight" rating and issued a $110.00 target price (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $84.20.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.